Involvement of c-jun in human liposarcoma growth: Supporting data from clinical immunohistochemistry and DNAzyme efficacy

Cancer Biology and Therapy

Volumn 7, Issue 8, 2008, Pages 1297-1301

  Dass, Crispin R ^a,b   Galloway, Stuart J ^b   Clark, Jonathan C M ^a   Khachigian, Levon M ^c   Choong, Peter F M ^a,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Apoptosis; C jun; Cancer; Deoxyribozyme; Gene therapy; Liposarcoma; Orthotopic

Indexed keywords

CASPASE 10; DEOXYRIBOZYME; DNAZYME; DZ13; FAS ANTIGEN; FAS LIGAND; PROTEIN C FOS; PROTEIN C JUN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 49749141097     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.8.6301     Document Type: Article

References (23)

1. Lucas DR, Nascimento AG, Sanjay BK, Rock MG. Well-differentiated liposarcoma. The Mayo Clinic experience with 58 cases. Am J Clin Pathol 1994 102:677-83.
2. Linehan DC, Lewis JJ, Leung D, Brennan MF. Influence of biologic factors and anatomic site in completely resected liposarcoma. J Clin Oncol 2000; 18:1637-43.
3. Issakov J, Soyfer V, Kollender Y, Bickels J, Meller I, Merimsky O. Liposarcoma in adult limbs treated by limb-sparing surgery and adjuvant radiotherapy. J Bone Joint Surg Br 2006; 88:1647-51.
4. Fabre-Guillevin E, Coindre JM, Somerhausen Nde S, Bonichon F, Stoeckle E, Bui NB. Retroperitoneal liposarcomas: follow-up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomas. Cancer 2006; 106:2725-33.
5. Mariani O, Brennetot C, Coindre JM, Gruel N, Ganem C, Delattre O, Stern MH, Aurias A. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 2007; 11:361-74.
6. LaPensee EW, Reddy SP, Hugo ER, Schwemberger SJ, Ben-Jonathan N. LS14 cells: a model for chemoresistance in liposarcoma. Cancer Biol Ther 2007; 6:519-24.
7. Thallinger C, Wolschek MF, Maierhofer H, Skvara H, Pehamberger H, Monia BP, Jansen B, Wacheck V, Selzer E. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin Cancer Res 2004; 10:4185-91.
8. Almog N, Henke V, Flores L, Hlatky L, Kung AL, Wright RD, Berger R, Hutchinson L, Naumov GN, Bender E, Akslen LA, Achilles EG, Folkman J. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J 2006; 20:947-9.
9. Wang D, Jensen RH, Williams KE, Pallavicini MG. Differential protein expression in MCF7 breast cancer cells transfected with ErbB2, neomycin resistance and luciferase plus yellow fluorescent protein. Proteomics 2004; 4:2175-83.
10. Dass CR, Choong PF. GFP expression alters osteosarcoma cell biology. DNA Cell Biol 2007; 26:599-601.
11. Santoro SW and Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997; 94:4262-6.
12. Dass CR, Choong PFM and Khachigian LM. DNAzyme technology and cancer therapy: Cleave and let die. Mol Cancer Ther 2008; 7:in press.
13. Bhindi R, Fahmy RG, Lowe HC, Chesterman CN, Dass CR, Cairns MJ, Saravolac EG, Sun LQ, Khachigian LM. Brothers in arms: DNAzymes, siRNA and the emerging wave of small molecule nucleic acid-based gene silencing strategies. Am J Pathol 2007; 171:1079-88.
14. Zhang G, Dass CR, Sumithran E, Di Girolamo N, Sun LQ and Khachigian LM. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 2004; 96:683-96.
15. Dass CR and Choong PFM. Dz13: a potential therapeutic molecule for cancer therapy via c-jun oncogene downregulation. Pharmazie 2008; 63:in press.
16. Ek ET, Dass CR, Contreras KG and Choong PF. Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor. Clin Exp Mets 2007; 24:93-106.
17. Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM. Early Growth Response factor-1: A key mediator of tumor angiogenesis and neovascularisation. Nat Med 2003; 9:1026-32.
18. Fahmy R, Waldman A, Zhang G, Mitchell A, Tedla N, Cai H, Chesterman CN, Geczy CR, Perry MA and Khachigian LM. Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. Nature Biotech 2006; 24:856-63.
19. Kilpatrick SE, Doyon J, Choong PF, Sim FH, Nascimento AG. The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer 1996; 77:1450-8.
20. Hui AC, Ngan SY, Wong K, Powell G, Choong PF. Preoperative radiotherapy for soft tissue sarcoma: the Peter MacCallum Cancer Centre experience. Eur J Surg Oncol 2006; 32:1159-64.
21. Alnemri ES. Mammalian cell death proteases: a family of highly conserved aspartate specific cysteine proteases. J Cell Biochem 1997; 64:33-42.
22. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Rohl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441:111-4.
23. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007; 448:39-43.